{"transactions":[{"id":895663,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2026-02-18T22:05:05.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":7269,"price":1.89,"value":13738.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person."}],"balance_after":299881,"source":{"system":"sec-edgar","filing":"0001470831-26-000178","document":"wk-form4_1771452301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000147083126000178/wk-form4_1771452301.xml","form_type":"4"}},{"id":895662,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2026-02-18T22:05:05.000Z","date":"2026-02-14","kind":"exercise","planned":false,"acquired":true,"shares":20950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025."}],"balance_after":307150,"source":{"system":"sec-edgar","filing":"0001470831-26-000178","document":"wk-form4_1771452301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000147083126000178/wk-form4_1771452301.xml","form_type":"4"}},{"id":895661,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2026-02-18T22:05:05.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1735,"price":1.89,"value":3279.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person."}],"balance_after":307150,"source":{"system":"sec-edgar","filing":"0001470831-26-000178","document":"wk-form4_1771452301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000147083126000178/wk-form4_1771452301.xml","form_type":"4"}},{"id":895660,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2026-02-18T22:05:05.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025."}],"balance_after":308885,"source":{"system":"sec-edgar","filing":"0001470831-26-000178","document":"wk-form4_1771452301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000147083126000178/wk-form4_1771452301.xml","form_type":"4"}},{"id":895659,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2026-02-18T22:05:05.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones."}],"balance_after":308885,"source":{"system":"sec-edgar","filing":"0001470831-26-000178","document":"wk-form4_1771452301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000147083126000178/wk-form4_1771452301.xml","form_type":"4"}},{"id":1263225,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:54:57.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":84700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025."}],"balance_after":84700,"derivative":{"exercise_price":3.18,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":84700},"source":{"system":"sec-edgar","filing":"0001662579-25-000017","document":"wk-form4_1739915691.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257925000017/wk-form4_1739915691.xml","form_type":"4"}},{"id":1263224,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:54:57.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":2368,"price":3.18,"value":7530.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") and does not represent a sale by the Reporting Person."}],"balance_after":108885,"source":{"system":"sec-edgar","filing":"0001662579-25-000017","document":"wk-form4_1739915691.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257925000017/wk-form4_1739915691.xml","form_type":"4"}},{"id":1263223,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:54:57.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":56500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026."}],"balance_after":111253,"source":{"system":"sec-edgar","filing":"0001662579-25-000017","document":"wk-form4_1739915691.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257925000017/wk-form4_1739915691.xml","form_type":"4"}},{"id":1263222,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:54:57.000Z","date":"2025-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1735,"price":3.2,"value":5552.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") and does not represent a sale by the Reporting Person."}],"balance_after":54753,"source":{"system":"sec-edgar","filing":"0001662579-25-000017","document":"wk-form4_1739915691.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257925000017/wk-form4_1739915691.xml","form_type":"4"}},{"id":1368142,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2024-11-12T21:17:22.000Z","date":"2024-11-07","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":10500,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001662579-24-000102","document":"wk-form4_1731446234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000102/wk-form4_1731446234.xml","form_type":"4"}},{"id":1368141,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-11-12T21:17:22.000Z","date":"2024-11-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":1102,"price":6.04,"value":6656.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":56488,"source":{"system":"sec-edgar","filing":"0001662579-24-000102","document":"wk-form4_1731446234.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000102/wk-form4_1731446234.xml","form_type":"4"}},{"id":1368140,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-11-12T21:17:22.000Z","date":"2024-11-07","kind":"exercise","planned":false,"acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":57590,"source":{"system":"sec-edgar","filing":"0001662579-24-000102","document":"wk-form4_1731446234.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000102/wk-form4_1731446234.xml","form_type":"4"}},{"id":1404569,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2024-09-17T21:12:06.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":14250,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001662579-24-000080","document":"wk-form4_1726607520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000080/wk-form4_1726607520.xml","form_type":"4"}},{"id":1404568,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-09-17T21:12:06.000Z","date":"2024-09-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":661,"price":6.36,"value":4203.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":53840,"source":{"system":"sec-edgar","filing":"0001662579-24-000080","document":"wk-form4_1726607520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000080/wk-form4_1726607520.xml","form_type":"4"}},{"id":1404567,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-09-17T21:12:06.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":54501,"source":{"system":"sec-edgar","filing":"0001662579-24-000080","document":"wk-form4_1726607520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000080/wk-form4_1726607520.xml","form_type":"4"}},{"id":1585917,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-09T00:24:23.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":78500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022."}],"balance_after":78500,"derivative":{"exercise_price":19,"expiration_date":"2032-02-13","underlying":"Common Stock","underlying_shares":78500},"source":{"system":"sec-edgar","filing":"0001662579-24-000028","document":"wk-form4_1709943848.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000028/wk-form4_1709943848.xml","form_type":"4"}},{"id":1585916,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-09T00:24:23.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":78500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022."}],"balance_after":0,"derivative":{"exercise_price":22.71,"expiration_date":"2032-02-13","underlying":"Common Stock","underlying_shares":78500},"source":{"system":"sec-edgar","filing":"0001662579-24-000028","document":"wk-form4_1709943848.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000028/wk-form4_1709943848.xml","form_type":"4"}},{"id":1585915,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-09T00:24:23.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":92000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this option vested and became exercisable on January 11, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":92000,"derivative":{"exercise_price":19,"expiration_date":"2031-01-10","underlying":"Common Stock","underlying_shares":92000},"source":{"system":"sec-edgar","filing":"0001662579-24-000028","document":"wk-form4_1709943848.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000028/wk-form4_1709943848.xml","form_type":"4"}},{"id":1585914,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-09T00:24:23.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":92000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this option vested and became exercisable on January 11, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":37.46,"expiration_date":"2031-01-10","underlying":"Common Stock","underlying_shares":92000},"source":{"system":"sec-edgar","filing":"0001662579-24-000028","document":"wk-form4_1709943848.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000028/wk-form4_1709943848.xml","form_type":"4"}},{"id":1640526,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T22:05:14.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":122800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024."}],"balance_after":122800,"derivative":{"exercise_price":7.31,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":122800},"source":{"system":"sec-edgar","filing":"0001662579-24-000017","document":"wk-form4_1708034697.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000017/wk-form4_1708034697.xml","form_type":"4"}},{"id":1640525,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-02-15T22:05:14.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":27300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025."}],"balance_after":52251,"source":{"system":"sec-edgar","filing":"0001662579-24-000017","document":"wk-form4_1708034697.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000017/wk-form4_1708034697.xml","form_type":"4"}},{"id":1640524,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-02-15T22:05:14.000Z","date":"2024-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1735,"price":6.53,"value":11329.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") and does not represent a sale by the Reporting Person."}],"balance_after":24951,"source":{"system":"sec-edgar","filing":"0001662579-24-000017","document":"wk-form4_1708034697.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000017/wk-form4_1708034697.xml","form_type":"4"}},{"id":1776832,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-19T23:23:54.000Z","date":"2023-09-18","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on September 18, 2025, subject to the Reporting Person's continued service on such date."}],"balance_after":120000,"derivative":{"exercise_price":2.15,"expiration_date":"2033-09-17","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001662579-23-000101","document":"wk-form4_1695165826.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000101/wk-form4_1695165826.xml","form_type":"4"}},{"id":1791701,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-08-31T20:10:58.000Z","date":"2023-08-30","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":16500,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001662579-23-000083","document":"wk-form4_1693512648.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000083/wk-form4_1693512648.xml","form_type":"4"}},{"id":1791700,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2023-08-31T20:10:58.000Z","date":"2023-08-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":661,"price":2.93,"value":1936.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":26686,"source":{"system":"sec-edgar","filing":"0001662579-23-000083","document":"wk-form4_1693512648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000083/wk-form4_1693512648.xml","form_type":"4"}},{"id":1791699,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2023-08-31T20:10:58.000Z","date":"2023-08-30","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":27347,"source":{"system":"sec-edgar","filing":"0001662579-23-000083","document":"wk-form4_1693512648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000083/wk-form4_1693512648.xml","form_type":"4"}},{"id":2013146,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-15T21:45:06.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 13, 2023."}],"balance_after":90000,"derivative":{"exercise_price":5.67,"expiration_date":"2033-02-12","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001662579-23-000036","document":"wf-form4_167649749262715.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000036/wf-form4_167649749262715.xml","form_type":"4"}},{"id":2013145,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2023-02-15T21:45:06.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 13, 2024."}],"balance_after":25097,"source":{"system":"sec-edgar","filing":"0001662579-23-000036","document":"wf-form4_167649749262715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000036/wf-form4_167649749262715.xml","form_type":"4"}},{"id":2038214,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-02-01T21:09:34.000Z","date":"2023-01-30","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":18750,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001662579-23-000020","document":"wf-form4_167528575707675.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000020/wf-form4_167528575707675.xml","form_type":"4"}},{"id":2038213,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2023-02-01T21:09:34.000Z","date":"2023-01-30","kind":"tax_withholding","acquired":false,"shares":1301,"price":7.78,"value":10121.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":5097,"source":{"system":"sec-edgar","filing":"0001662579-23-000020","document":"wf-form4_167528575707675.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000020/wf-form4_167528575707675.xml","form_type":"4"}},{"id":2038212,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2023-02-01T21:09:34.000Z","date":"2023-01-30","kind":"exercise","acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":6398,"source":{"system":"sec-edgar","filing":"0001662579-23-000020","document":"wf-form4_167528575707675.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000020/wf-form4_167528575707675.xml","form_type":"4"}},{"id":2232207,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2022-06-14T20:45:36.000Z","date":"2022-05-26","kind":"tax_withholding","acquired":false,"shares":1102,"price":7.01,"value":7725.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":2648,"source":{"system":"sec-edgar","filing":"0001209191-22-036713","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122036713/doc4a.xml","form_type":"4/A","original_submission_date":"2022-05-27"}},{"id":2252693,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2022-05-27T20:16:03.000Z","date":"2022-05-25","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":22500,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001209191-22-032512","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122032512/doc4.xml","form_type":"4"}},{"id":2252692,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2022-05-27T20:16:03.000Z","date":"2022-05-25","kind":"exercise","acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":3750,"source":{"system":"sec-edgar","filing":"0001209191-22-032512","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122032512/doc4.xml","form_type":"4"}},{"id":2978810,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:46:00.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-20-126328","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126328/a4.xml","form_type":"4"}},{"id":2978809,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:46:00.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":6900,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6900},"source":{"system":"sec-edgar","filing":"0001104659-20-126328","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126328/a4.xml","form_type":"4"}},{"id":2978808,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:46:00.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":7000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001104659-20-126328","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126328/a4.xml","form_type":"4"}},{"id":2978807,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2020-11-17T15:46:00.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":28155,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. (\"Parent\"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of November 16, 2020 (the \"Effective Time\"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive $13.75 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. (\"Parent\"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of November 16, 2020 (the \"Effective Time\"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive $13.75 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-126328","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126328/a4.xml","form_type":"4"}},{"id":3182012,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2020-04-06T20:26:27.000Z","date":"2020-04-02","kind":"tax_withholding","acquired":false,"shares":79,"price":6.18,"value":488.22,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 267 restricted stock units on April 2, 2020"}],"balance_after":28155,"source":{"system":"sec-edgar","filing":"0000792977-20-000031","document":"wf-form4_158621916919826.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297720000031/wf-form4_158621916919826.xml","form_type":"4"}},{"id":3214557,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-12T16:11:34.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter."}],"balance_after":17000,"derivative":{"exercise_price":7.27,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-20-032485","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920032485/a4.xml","form_type":"4"}},{"id":3214556,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2020-03-12T16:11:34.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":13000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's 2019 Equity Incentive Plan(the \"Plan\") that will vest in three equal annual installments with the first installment vesting on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."}],"balance_after":28234,"source":{"system":"sec-edgar","filing":"0001104659-20-032485","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920032485/a4.xml","form_type":"4"}},{"id":3229621,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2020-03-04T17:50:21.000Z","date":"2020-03-02","kind":"tax_withholding","acquired":false,"shares":358,"price":7.75,"value":2774.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 1,032 restricted stock units on March 2, 2020."}],"balance_after":15234,"source":{"system":"sec-edgar","filing":"0001104659-20-029295","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920029295/a4.xml","form_type":"4"}},{"id":3250880,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2020-02-25T16:44:42.000Z","date":"2020-02-25","kind":"tax_withholding","acquired":false,"shares":1095,"price":8.84,"value":9679.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 3,159 restricted stock units on February 25, 2020."}],"balance_after":15592,"source":{"system":"sec-edgar","filing":"0000792977-20-000017","document":"wf-form4_158266706373546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297720000017/wf-form4_158266706373546.xml","form_type":"4"}},{"id":3250879,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":65841,"kind":"person","name":"Schick Kelly","position":1,"cik":"0001797388","reported_name":"Schick Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2020-02-25T16:44:42.000Z","date":"2020-02-23","kind":"tax_withholding","acquired":false,"shares":463,"price":9.5,"value":4398.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 1,334 restricted stock units on February 23, 2020."}],"balance_after":16687,"source":{"system":"sec-edgar","filing":"0000792977-20-000017","document":"wf-form4_158266706373546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297720000017/wf-form4_158266706373546.xml","form_type":"4"}}]}